Well Pharma Medical Research

Well Pharma Medical Research

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Well Pharma Medical Research is a US-based clinical research site organization providing trial execution services for pharmaceutical and biotech sponsors. Founded and led by Dr. Eddie Armas, the company operates two dedicated units for early and late-phase trials, supported by an on-site CLIA-certified lab, secure pharmacy, and proficiency with major electronic data capture systems. Its business model is service-based, generating revenue from conducting clinical trials for external partners across indications like dermatology, respiratory, and metabolic diseases. The company's outlook is tied to the robust clinical trial activity in South Florida and its established investigator network.

DermatologyMetabolic DisordersRespiratory DiseasesNeurology

Technology Platform

Clinical research site infrastructure with two dedicated trial units (early & late phase), an on-site CLIA/IATA/OSHA certified laboratory, a secure pharmacy, and proficiency with major EDC systems (Oracle Rave, Medidata, Medrio, Inform).

Opportunities

The growing trend of pharmaceutical outsourcing to CROs and specialized sites, combined with the high demand for diverse patient populations in South Florida, presents a strong market opportunity.
Expanding its therapeutic reach or forming preferred partnerships with large CROs could drive further growth.

Risk Factors

Revenue is project-based and reliant on winning competitive site selections.
The business faces key-person risk centered on its founder/Principal Investigator and is susceptible to patient recruitment challenges and regulatory compliance issues that could threaten its operational status.

Competitive Landscape

WPMR competes with other clinical research sites and site networks in the active South Florida region and nationally. Competition is based on patient recruitment speed, data quality, investigator reputation, and site capabilities. Its on-site lab and phase I-IV expertise are key differentiators.